DHP 1401

Drug Profile

DHP 1401

Alternative Names: DHP-1401

Latest Information Update: 04 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DAE HWA Pharmaceutical
  • Class
  • Mechanism of Action AMPA receptor modulators; Mitogen-activated protein kinase modulators; Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 03 Feb 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by DAE HWA Pharmaceutical
  • 28 Dec 2016 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in South Korea (PO) (NCT03055741)
  • 01 Dec 2016 Preclinical trials in Alzheimer's disease in South Korea (PO), before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top